Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
After finishing at $276.45 in the prior trading day, Elevance Health Inc (NYSE: ELV) closed at $281.72, up 1.91%. In other words, the price has increased by $1.91 from its previous closing price. On the day, 3.5 million shares were traded. ELV stock price reached its highest trading level at $283.46 during the session, while it also had its lowest trading level at $275.99.
Ratios:
Our goal is to gain a better understanding of ELV by taking a closer look at its different ratios. In the meantime, Its Debt-to-Equity ratio is 0.69 whereas as Long-Term Debt/Eq ratio is at 0.64.
On July 18, 2025, Leerink Partners Downgraded its rating to Market Perform which previously was Outperform but kept the price unchanged to $310.
Robert W. Baird Downgraded its Outperform to Neutral on April 15, 2025, while the target price for the stock was maintained at $529.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 18 ’25 when BOUDREAUX GAIL bought 8,500 shares for $286.94 per share. The transaction valued at 2,438,951 led to the insider holds 151,020 shares of the business.
Kaye Mark sold 4,588 shares of ELV for $1,949,074 on Apr 24 ’25. The EVP & CFO now owns 18,977 shares after completing the transaction at $424.82 per share. On Apr 24 ’25, another insider, Kaye Mark, who serves as the Officer of the company, bought 4,588 shares for $424.81 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELV now has a Market Capitalization of 63437148160 and an Enterprise Value of 57773543424. As of this moment, Elevance’s Price-to-Earnings (P/E) ratio for their current fiscal year is 11.99, and their Forward P/E ratio for the next fiscal year is 8.47. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.26. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.34 while its Price-to-Book (P/B) ratio in mrq is 1.45. Its current Enterprise Value per Revenue stands at 0.305 whereas that against EBITDA is 6.09.
Stock Price History:
The Beta on a monthly basis for ELV is 0.60, which has changed by -0.44989455 over the last 52 weeks, in comparison to a change of 0.16260707 over the same period for the S&P500. Over the past 52 weeks, ELV has reached a high of $567.26, while it has fallen to a 52-week low of $274.40. The 50-Day Moving Average of the stock is -23.63%, while the 200-Day Moving Average is calculated to be -29.81%.
Shares Statistics:
The stock has traded on average 2.00M shares per day over the past 3-months and 3450950 shares per day over the last 10 days, according to various share statistics. A total of 224.84M shares are outstanding, with a floating share count of 224.79M. Insiders hold about 0.17% of the company’s shares, while institutions hold 93.12% stake in the company. Shares short for ELV as of 1751241600 were 2539048 with a Short Ratio of 1.27, compared to 1748563200 on 2199507. Therefore, it implies a Short% of Shares Outstanding of 2539048 and a Short% of Float of 1.1199999999999999.
Dividends & Splits
In the trailing 12 months, ELV’s forward annual dividend rate was 6.68, compared to 6.68 this year. Against a Trailing Annual Dividend Yield of 0.0241635The stock’s 5-year Average Dividend Yield is 1.2. The current Payout Ratio is 25.39% for ELV, which recently paid a dividend on 2025-06-10 with an ex-dividend date of 2025-09-10. Stock splits for the company last occurred on 2005-06-01 when the company split stock in a 2:1 ratio.
Earnings Estimates
The firm’s stock currently is rated by 19.0 analysts. The consensus estimate for the next quarter is $4.26, with high estimates of $5.06 and low estimates of $1.96.
Analysts are recommending an EPS of between $34.57 and $28.77 for the fiscal current year, implying an average EPS of $30.88. EPS for the following year is $33.34, with 21.0 analysts recommending between $39.23 and $26.97.
Revenue Estimates
10 analysts predict $49.18B in revenue for the current quarter. It ranges from a high estimate of $50.2B to a low estimate of $48.14B. As of the current estimate, Elevance Health Inc’s year-ago sales were $44.72BFor the next quarter, 10 analysts are estimating revenue of $49.38B. There is a high estimate of $50.9B for the next quarter, whereas the lowest estimate is $47.78B.
A total of 13 analysts have provided revenue estimates for ELV’s current fiscal year. The highest revenue estimate was $199.04B, while the lowest revenue estimate was $193.24B, resulting in an average revenue estimate of $196.35B. In the same quarter a year ago, actual revenue was $175.2BBased on 11 analysts’ estimates, the company’s revenue will be $207.73B in the next fiscal year. The high estimate is $211.25B and the low estimate is $200.55B.
